127 related articles for article (PubMed ID: 32111758)
1. Effects of Cinnamaldehyde on the Viability and Expression of Chemokine Receptor Genes in Temozolomide-treated Glioma Cells.
Chen JC; Hsieh PS; Chen SM; Hwang JH
In Vivo; 2020; 34(2):595-599. PubMed ID: 32111758
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy.
Hwang TW; Kim DH; Kim DB; Jang TW; Kim GH; Moon M; Yoon KA; Choi DE; Park JH; Kim JJ
Int J Mol Med; 2019 Mar; 43(3):1478-1486. PubMed ID: 30664150
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Oliveira KA; Dal-Cim T; Lopes FG; Ludka FK; Nedel CB; Tasca CI
Mol Neurobiol; 2018 Feb; 55(2):1509-1523. PubMed ID: 28181188
[TBL] [Abstract][Full Text] [Related]
5. Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Oliveira KA; Dal-Cim TA; Lopes FG; Nedel CB; Tasca CI
Purinergic Signal; 2017 Sep; 13(3):305-318. PubMed ID: 28536931
[TBL] [Abstract][Full Text] [Related]
6. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
7. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
8. Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Chio CC; Chen KY; Chang CK; Chuang JY; Liu CC; Liu SH; Chen RM
BMC Cancer; 2018 Apr; 18(1):379. PubMed ID: 29614990
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
10. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
11. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
12. Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Zeng X; Wang Q; Tan X; Jia L; Li Y; Hu M; Zhang Z; Bai X; Zhu Y; Yang X
J Nanobiotechnology; 2019 Apr; 17(1):47. PubMed ID: 30935403
[TBL] [Abstract][Full Text] [Related]
13. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
14. Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Szymczak B; Czarnecka J; Czach S; Nowak W; Roszek K
Cell Signal; 2023 Jun; 106():110641. PubMed ID: 36858191
[TBL] [Abstract][Full Text] [Related]
15. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
16. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Ni Q; Fan Y; Zhang X; Fan H; Li Y
J Ethnopharmacol; 2019 Oct; 242():111699. PubMed ID: 31005632
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
19. Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats.
Chen JC; Hwang JH
In Vivo; 2019; 33(4):1203-1208. PubMed ID: 31280210
[TBL] [Abstract][Full Text] [Related]
20. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
